I

    In8bio Inc (INAB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.10
    +0.07 (+6.28%)

    Market Cap: $10.84M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    59%(13/22)
    Avg Surprise
    +1.05%
    Streak
    5 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.34
    Range$-0.57 - $-0.22
    3 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.23+33.2%
    60d ago$-0.38-12.9%
    30d ago$-0.38-12.9%
    7d ago$-0.38-12.9%
    Current$-0.34
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.31
    Range$-0.09 - $0.51
    4 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.31---
    Sep 26EST
    		-$-0.34---
    Jun 26
    Reported Aug 6
    		$-0.25N/A+59.02%Beat+79.8%
    Mar 26
    Reported May 7
    		$-0.26N/A+62.32%Beat+87.6%
    Dec 25
    Reported Mar 12
    		$-0.45$-0.47+5.26%Beat-462.5%
    Sep 25
    Reported Nov 6
    		$-0.85$-1.25+32.00%Beat+81.1%
    Jun 25
    Reported Aug 7
    		$-1.24$-1.50+17.33%Beat+78.2%
    Mar 25
    Reported May 7
    		$-2.10$-2.00-5.00%Miss+65.0%
    Dec 24
    Reported Mar 13
    		$-0.08$-0.07-14.29%Miss+61.9%
    Sep 24
    Reported Nov 12
    		$-4.50$-4.72+4.66%Beat+34.8%
    Jun 24
    Reported Aug 8
    		$-5.70$-5.04-13.10%Miss+29.6%
    Mar 24
    Reported May 9
    		$-6.00$-5.18-15.83%Miss+33.3%
    Dec 23
    Reported Mar 14
    		$-0.21$-0.15-40.00%Miss+43.2%
    Sep 23
    Reported Nov 9
    		$-6.90$-7.35+6.12%Beat+32.4%
    Jun 23
    Reported Aug 10
    		$-8.10$-8.10+0.00%Beat+28.9%
    Mar 23
    Reported May 12
    		$-9.00$-9.60+6.25%Beat+9.1%
    Dec 22
    Reported Mar 30
    		$-0.37$-0.32-15.63%Miss-76.2%
    Sep 22
    Reported Nov 10
    		$-10.20$-8.10-25.93%Miss-36.0%
    Jun 22
    Reported Aug 12
    		$-11.40$-8.70-31.03%Miss-1972.7%
    Mar 22
    Reported May 12
    		$-9.90$-9.90+0.00%Beat-1107.3%
    Dec 21
    Reported Mar 17
    		$-0.21$-0.26+19.23%Beat+74.2%
    Sep 21
    Reported Nov 10
    		$-7.50$-8.25+9.09%Beat-2400.0%
    Jun 21
    Reported Jul 30
    		$-0.55$-0.40-37.50%Miss+20.5%
    Mar 21
    Reported Jun 2
    		$-0.82$-0.82+0.00%Beat-38.9%
    Dec 20
    Reported Mar 31
    		$-0.82$0.00N/AMiss-70.2%
    Sep 20
    Reported Nov 5
    		$-0.30$0.00N/AMiss+37.4%
    Jun 20
    Reported Sep 30
    		$-0.69$0.00N/AMiss-327.8%
    Dec 19
    Reported Mar 30
    		$-0.59$0.00N/AMiss-264.8%
    Sep 19
    Reported Dec 31
    		$-0.48$0.00N/AMiss-
    Jun 19
    Reported Sep 30
    		$-0.48$0.00N/AMiss-
    Mar 19
    Reported Jun 29
    		$-0.16$0.00N/AMiss-
    Dec 18
    Reported Mar 30
    		$-0.16$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.61EV/EBITDA-1.15x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-111.10%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio8.21xQuick Ratio8.21x
    Trading Statistics
    Beta0.28Avg Volume76.25K
    52-Week High$2.7352-Week Low$0.88

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.15
    SMA 20$1.09
    SMA 50$1.22
    SMA 200$1.61
    EMA 10$1.12
    EMA 20$1.13
    EMA 50$1.21
    EMA 200$1.75

    MACD

    Line: -0.02Signal: -0.03Hist: 0.00

    ADX

    ADX: 26.5+DI: 19.7-DI: 28.9

    Aroon & PSAR

    Aroon Up80.0
    Aroon Down48.0
    PSAR$1.29

    Bollinger Bands

    Upper Band$1.29
    Lower Band$0.90
    %B Position3560%(Upper)
    Band Width0.52

    RSI (14-Day)

    Neutral
    46.6

    Momentum Oscillators

    Stoch %K42.5
    Stoch %D50.5
    Williams %R-47.6
    ROC (10d)-0.9%
    Momentum-0.01
    CCI (20d)-5.7
    MFI (14d)64.6

    Volatility Measures

    ATR (14d)$0.10(9.0%)
    StdDev (20d)0.10
    Hist Vol101.6%(High)

    Volume Flow

    VWAP$1.08
    OBV-116.1M
    AD Line98.1B
    CMF (20d)0.300

    Volume Metrics

    Avg Vol (20d)72.5K
    Vol Ratio0.5x
    VWMA (20d)$1.11

    Pivot Points

    R3$1.07
    R2$1.06
    R1$1.05
    Pivot Point$1.04
    S1$1.03
    S2$1.02
    S3$1.01

    Advanced Oscillators

    TSI-6.69
    Ultimate Osc52.5
    KST-24.04

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$2.53M$0$0$0$3.75M$0
    Cost of Revenue$0$0$1.17M$0$0$0$1.26M$0$0$0$627,000$0
    Gross Profit$0$0$-1,173,000$0$0$0$-702,000$0$0$0$3.12M$0
    Operating Expenses$4.93M$5.27M$5.03M$3.97M$5.20M$5.66M$6.22M$7.11M$8.69M$8.64M$7.60M$7.17M
    R&D$2.49M$2.61M$2.65M$2.10M$2.49M$2.97M$3.59M$3.31M$5.16M$4.90M$4.52M$3.79M
    SG&A$2.44M$2.65M$2.38M$1.86M$2.71M$2.69M$2.63M$2.73M$3.53M$3.74M$3.08M$3.38M
    Operating Income$-4,781,000$-5,090,000$-4,942,000$-3,854,000$-5,094,000$-5,550,000$-6,160,000$-7,086,000$-8,629,000$-8,562,000$-7,598,000$-7,169,000
    Interest Income$154,000$176,000$91,000$113,000$107,000$110,000$64,000$23,000$60,000$83,000$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-4,781,000$-5,090,000$-4,942,000$-3,854,000$-5,094,000$-5,550,000$-6,096,000$-7,063,000$-8,569,000$-8,479,000$-7,598,000$-7,169,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-4,781,000$-5,090,000$-4,942,000$-3,854,000$-5,094,000$-5,550,000$-6,160,000$-7,086,000$-8,629,000$-8,562,000$-7,598,000$-7,169,000
    EBITDA$-4,324,000$-4,590,000$-4,421,000$-3,327,000$-4,310,000$-4,881,000$-5,458,000$-6,396,000$-7,998,000$-7,930,000$-6,971,000$-6,522,000
    EBIT$-4,781,000$-5,090,000$-4,942,000$-3,854,000$-5,094,000$-5,550,000$-6,160,000$-7,086,000$-8,629,000$-8,562,000$-7,598,000$-7,169,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about INAB

    News

    IN8BIO, Inc. (INAB) investor discloses 9.99% stake and warrant holdings

    Laurence W. Lytton and the Lytton-Kambara Foundation have filed an amended ownership report for IN8BIO, Inc. (INAB), indicating a beneficial ownership of 1,056,513 shares, which includes common stock and warrants, representing 9.99% of the company's outstanding shares. This stake is subject to a 9.99% beneficial ownership limitation. Both Lytton and the Foundation hold shared voting and dispositive power over these securities.

    Stock Titan•8/13/26•
    Neutral

    IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    IN8bio, Inc. announced that its Compensation Committee granted a nonqualified stock option to a new employee for 4,000 shares of common stock. This inducement grant, made under Nasdaq Listing Rule 5635(c)(4), is part of the Company's 2026 Inducement Plan. The stock option will vest over four years, tied to continued employment.

    GlobeNewswire•8/11/26•
    Somewhat-Bullish

    IN8bio Inc (6JH0.MU) Analyst insights, Price targets and Recommendations

    The article provides a snapshot of analyst insights for IN8bio Inc (6JH0.MU), highlighting a reiteration of a "Buy" rating by HC Wainwright & Co. on March 13, 2026. It also presents the current stock price and links to various financial data points for the company.

    Yahoo Finance UK•8/11/26•
    Bullish

    IN8bio New Employee Receives Option Set to Vest Over Four Years

    IN8bio (Nasdaq: INAB) announced that its Board Compensation Committee granted a new employee a nonqualified stock option to purchase 4,000 shares of common stock. This inducement award, effective August 3, 2026, falls under the company's 2026 Inducement Plan and Nasdaq Listing Rule 5635(c)(4). The option will vest over four years, with 25% vesting on the first work anniversary and the remainder in 36 equal monthly installments, contingent on continued employment.

    Stock Titan•8/10/26•
    Somewhat-Bullish

    IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    IN8bio, Inc. announced that its Compensation Committee granted a nonqualified stock option for 4,000 shares of common stock to a new employee. This grant, with a grant date of August 3, 2026, was made as an inducement for employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option will vest over four years, with 25% vesting on the first anniversary and the remainder in 36 equal monthly installments, subject to continuous employment.

    Yahoo Finance Singapore•8/10/26•
    Neutral

    Frequently Asked Questions About INAB

    Does INAB pay dividends?
    In8bio Inc (INAB) does not currently pay a regular dividend.
    What is INAB's market cap?
    In8bio Inc (INAB) has a market capitalization of $10.84M with a current stock price of $1.10.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In